# Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

> **NCT04472598** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 252 (actual)

## Conditions studied

- Myelofibrosis (MF)

## Interventions

- **DRUG:** Placebo for Navitoclax
- **DRUG:** Ruxolitinib
- **DRUG:** Navitoclax

## Key facts

- **NCT ID:** NCT04472598
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-29
- **Primary completion:** 2023-04-13
- **Final completion:** 2025-01-29
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04472598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04472598, "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT04472598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*